Clinical and Regulatory Aspects of Allergen Immunotherapy and Biologics


Rome, 27th - 29th April 2017
Preliminary programme

Thursday, April 27th, 2017

8.30 Session 0 – Food allergy: biological facts

08.30 – 08.50 Hygiene is the driving cause of the allergy epidemics
08.50 – 09.10 Intraterine Programming is as important as hygiene
09.10 – 10.00 Discussion and vote

10.00 – 10.30 meeting opening address

10.30 – 11.00 Lecture - The allergy epidemics. Where we are? Ignacio Ansotegui

11.00 Session 1 – Controversies in allergy prevention
11.00 – 11.20 Will pro- and prebiotics reduce the burden of allergic disease? - Ruby Pawankar
11.20 – 11.40 Are fish oils able to reduce the burden of wheeze and asthma?
11.40 – 12.00 Hydrolyzed infant formulas: do they reduce the risk of allergic disease?
12.00 – 12.20 Discussion and vote

12.20 – 12.45 Lecture - Role of innate immunity in allergy inception

13.00 -14.00 lunch break – Satellite symposium

14.00 Session 2 – Controversies in food allergy
14.00 – 14.20 The LEAP strategy must be limited to peanut - Hugh Sampson
14.20 – 14.40 Every food must be introduced early - Motohiro Ebisawa
14.40 – 15.00 Does OIT accelerate the resolution of food allergy? Mimi Tang
15.10 – 15.30 Discussion and vote

15.30-16.00 Lecture - Introduction of solid foods and food allergy – the next steps

16.00 - Session 3 – Controversies in pediatric asthma.
16.00 – 16.20 Topical steroids should be used continuously - Giorgio Piacentini
16.20 – 16.40 Topical steroids should be used intermittently - Brad Chipps
16.40 – 17.00 What is really effective treatment for children with moderate to severe asthma - Paul Greenberger
17.00 – 17.20 Discussion and vote

17.30- 18.00 Lecture: – drug allergy in adults and children. Antonino Romano
Friday, April 28, 2017

8.30 Session 4 - Controversies in allergen immunotherapy
08.30 - 08.50 Immunotherapy should be a regular drug - Walter Canonica
08.50 - 09.10 Immunotherapy should remain a compounded allergen mixture - Stephen Tilles
09.10 - 09.30 SLIT or SCTT, that is the question - Gianni Passalacqua
09.30 - 10.00 Discussion and vote

10.00 - Session 5 - Controversies in cow’s milk allergy (DRACMA session)
10.00 - 10.20 Milk intolerance: do it exist? - Alberto Martelli
10.20 - 10.40 Hydrolyzed CM formulae will keep the leadership among milk substitutes
10.40 - 11.00 Non CM (rice & AA formulae) will replace Hydrolyzed CM formulae
11.00 - 11.30 Discussion and vote

11.30 - 11.55 Lecture - DRACMA - Update & perspectives

12.00 - 13.00 - lunch break - Satellite symposium

13.00 - Session 6 - Controversies in pediatric asthma
13.00 - 13.20 Should systemic steroids be used in preschool children with recurrent wheezing? - Elham Hossny
13.20 - 13.40 Tiotropium in pediatric asthma
13.40 - 14.00 Role of FeNO in pediatric asthma - Jim Sublett
14.00 - 14.30 - Discussion and vote

14.30 Session 7 - Controversies in eosinophilic diseases
14.30 - 14.50 Atopic eczema as a target for biologics
14.50 - 15.10 EoE may be treated with elimination diet - Antonella Cianferoni
15.10 - 15.30 EoE as target for biologics - Amal Assa’ad
15.30 - 16.00 Discussion and vote

16.00 - 16.30 Lecture

16.40 Session 8: Probiotics in allergy
16.40 - 17.00 Microbiome and allergy: possible strategies of intervention. Hanja Szajewska
17.00 - 17.20 Primum non nocere: possible side affects of allergy treatments.
17.20 - 17.40 Adjuvants in AIT: the good, the bad, the ugly - Erika Jensen-Jarolim
17.40 - 18.00 Probiotics: health benefits and health claims in allergy medicine - H. Van Loweren
17.40 - 18.00 Discussion
Saturday, April 29th, 2017

**Regulatory Aspects of Immunotherapy and Biologics**

9.00 – 9.30  Keynote lecture: EMA initiatives for allergen immunotherapy and biologics

**Session 9: EMA, allergen products and biologics**
9.30 - 9.50  Adaptive Licensing
9.50 – 10.10 Mechanisms of immunotherapy
10.10 -10.30. Health Technology Assessment for allergen immunotherapy and biologics.
10.30 – 11.00. Discussion
11.00-11.30. Coffee break

**Session 10: Allergen products**
11.30 – 11.50 Allergy diagnosis. Will in vitro replace in vivo tests?
12.10 - 12.30 Pediatric Investigational Plans for allergen immunotherapy in children.
12.30 - 13.00. Discussion

**13.00 - 14.00 Lunch**

**14.00 Session 11: Biologics, Biosimilars… and more**
14.00 - 14.20 Targets for biologics
14.20 - 14.40 Biosimilars
14.40 - 15.00 Biomarkers for allergen immunotherapy and biologics
15.00 - 15.20 Advanced therapies for allergic and immunologic diseases.
15.20 - 15.40 Discussion

**15.40 – 16.20 Panel discussion: Allergen immunotherapy, Biologics and Biosimilars in the World**

**16.20- 16.30 Summing-up**